Head and Neck Cancers

  • Liam WelshEmail author
  • Kate Newbold
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


Clinical practice in treating head and neck cancers (HNC) makes use of 18F-fluorodeoxyglucose (FDG) PET/CT, but other tracers are under investigation and may provide additional clinically useful information [1].


  1. 1.
    Newbold K, Powell C. PET/CT in radiotherapy planning for head and neck cancer. Front Oncol. 2012;2:189.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Evangelista L, Cervino AR, Chondrogiannis S, Marzola MC, Maffione AM, Colletti PM, Muzzio PC, Rubello D. Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer: a systematic literature overview. Nucl Med Commun. 2014;35:123–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Rohde M, Dyrvig A-K, Johansen J, Sørensen JA, Gerke O, Nielsen AL, Høilund-Carlsen PF, Godballe C. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2014;50:2271–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Caldas-Magalhaes J, Kasperts N, Kooij N, van den Berg CAT, Terhaard CHJ, Raaijmakers CPJ, Philippens MEP. Validation of imaging with pathology in laryngeal cancer: accuracy of the registration methodology. Int J Radiat Oncol Biol Phys. 2012;82:e289–98.CrossRefPubMedGoogle Scholar
  5. 5.
    Thiagarajan A, Caria N, Schöder H, Iyer NG, Wolden S, Wong RJ, Sherman E, Fury MG, Lee N. Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. Int J Radiat Oncol Biol Phys. 2012;83:220–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Madani I, Duthoy W, Derie C, de Gersem W, Boterberg T, Saerens M, Jacobs F, Grégoire V, Lonneux M, Vakaet L, Vanderstraeten B, Bauters W, Bonte K, Thierens H, de Neve W. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:126–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Castadot P, Geets X, Lee JA, Grégoire V. Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol. 2011;101:343–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, Loft A, Kristensen CA, Specht L. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol. 2014;111:360–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Powell C, Schmidt M, Borri M, Koh D-M, Partridge M, Riddell A, Cook G, Bhide SA, Nutting CM, Harrington KJ, Newbold KL. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol. 2013;106:112–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, Murthy V, Budrukkar A. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–95.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Head and Neck UnitRoyal Marsden NHS Foundation TrustLondonUK

Personalised recommendations